- Home
- CPRX vs VKTX Comparison
CPRX vs VKTX Comparison
Compare CPRX & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- VKTX
- Stock Information
- Founded
- CPRX 2002
- VKTX 2012
- Country
- CPRX United States
- VKTX United States
- Employees
- CPRX N/A
- VKTX N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CPRX Health Care
- VKTX Health Care
- Exchange
- CPRX Nasdaq
- VKTX Nasdaq
- Market Cap
- CPRX 2.9B
- VKTX 2.8B
- IPO Year
- CPRX 2006
- VKTX 2015
- Fundamental
- Price
- CPRX $23.37
- VKTX $27.55
- Analyst Decision
- CPRX Strong Buy
- VKTX Buy
- Analyst Count
- CPRX 7
- VKTX 12
- Target Price
- CPRX $32.29
- VKTX $84.00
- AVG Volume (30 Days)
- CPRX 975.9K
- VKTX 4.3M
- Earning Date
- CPRX 05-07-2025
- VKTX 04-23-2025
- Dividend Yield
- CPRX N/A
- VKTX N/A
- EPS Growth
- CPRX 178.13
- VKTX N/A
- EPS
- CPRX 1.57
- VKTX N/A
- Revenue
- CPRX $534,645,999.00
- VKTX N/A
- Revenue This Year
- CPRX $15.59
- VKTX N/A
- Revenue Next Year
- CPRX $8.90
- VKTX N/A
- P/E Ratio
- CPRX $14.90
- VKTX N/A
- Revenue Growth
- CPRX 29.97
- VKTX N/A
- 52 Week Low
- CPRX $14.47
- VKTX $18.92
- 52 Week High
- CPRX $26.16
- VKTX $81.81
- Technical
- Relative Strength Index (RSI)
- CPRX 50.33
- VKTX 53.68
- Support Level
- CPRX $20.80
- VKTX $26.37
- Resistance Level
- CPRX $25.01
- VKTX $30.28
- Average True Range (ATR)
- CPRX 0.83
- VKTX 1.65
- MACD
- CPRX -0.06
- VKTX 0.27
- Stochastic Oscillator
- CPRX 61.05
- VKTX 56.53
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.